InflaRx (IFRX) Expected to Announce Earnings on Thursday

InflaRx (NASDAQ:IFRX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect InflaRx to post earnings of ($0.27) per share and revenue of $0.13 million for the quarter.

InflaRx Stock Down 6.5 %

Shares of IFRX stock traded down $0.08 during mid-day trading on Thursday, reaching $1.15. The stock had a trading volume of 123,754 shares, compared to its average volume of 212,759. The firm has a market cap of $77.20 million, a PE ratio of -1.06 and a beta of 1.98. InflaRx has a one year low of $1.14 and a one year high of $2.82. The firm's 50 day simple moving average is $2.08 and its 200 day simple moving average is $1.92.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of InflaRx in a research note on Friday, March 7th.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.